Manolete Partners PLC (MANO)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 38.00 |
|---|---|
| 52-week range | 32.00 – 90.00 |
| Return, 1 month / 3 months | −2.6% / −11.6% |
| Return, 1 year / 3 years | −55.6% / −75.5% |
| Trend | Below its 200-day average |
| RSI (14) | 48 |
| Volatility (1 year) | 57.0% |
| Worst drawdown (1 year) | -62.2% |
| Average daily value traded | 1.54M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Manolete Partners funds and manages litigation arising from insolvency situations, working with insolvency practitioners and other parties who hold legal claims. The firm acquires or finances claims connected with failed businesses and pursues recoveries through the courts, sharing in the proceeds when cases succeed. It is based in the United Kingdom and deals mainly with claims tied to insolvent estates and the professionals who administer them.
Manolete Partners PLC trades under the code MANO on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Manolete Partners PLC (MANO) trades on the London Exchange in UK. It last closed at GBX 38.00 on 23 October 2026.
Its price-based Market X-Ray is 22 out of 100 (a weak price profile), ranking 3,372 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 55.6% and over the last three months it fell 11.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 14 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -15.4% | ||
| From 52-week high | -57.8% | ||
| Momentum | 15 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -11.6% | ||
| 6-month return | -24.0% | ||
| 12-month return, skipping the last month | -54.4% | ||
| Stability (higher is calmer) | 17 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 57.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -62.2% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.54M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −2.6% |
| 3 months | −11.6% |
| 6 months | −24.0% |
| 1 year | −55.6% |
| 3 years | −75.5% |
| 5 years | −87.7% |
Signals
| 50-day / 200-day average | 38.60 / 44.94 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.66 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 Sep 2022 | GBP 0.0050 |
| 16 Dec 2021 | GBP 0.0039 |
| 9 Sep 2021 | GBP 0.0100 |
| 26 Nov 2020 | GBP 0.0117 |
| 10 Sep 2020 | GBP 0.0300 |
| 12 Dec 2019 | GBP 0.0050 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.